FDA approved new test for early detection of Alzheimer’s disease
- Why Lecanemab’s Adoption Faces an Uphill Battle in US?
- Yogurt and High LDL Cholesterol: Can You Still Enjoy It?
- WHO Releases Global Influenza Vaccine Market Study in 2024
- HIV Infections Linked to Unlicensed Spa’s Vampire Facial Treatments
- A Single US$2.15-Million Injection to Block 90% of Cancer Cell Formation
- WIV: Prevention of New Disease X and Investigation of the Origin of COVID-19
FDA approved new test for early detection of Alzheimer’s disease
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
FDA approved new test for early detection of Alzheimer’s disease.
The U.S. Food and Drug Administration (FDA) has approved a new test for Alzheimer’s disease.
The test is the first in vitro diagnostic tool for Alzheimer’s approved for use in the United States. It is reported that the tool makes a diagnosis by measuring the level of amyloid in the spinal fluid.
Doctors and patients currently have few tools to diagnose Alzheimer’s disease. Aside from cognitive and psychological testing, the only way to diagnose Alzheimer’s disease is to perform a positron emission tomography (PET).
These scans measure levels of damaging amyloid and tau proteins in the brain, but they are expensive and unavailable to many patients.
The new tool, called the Lumipulse test, can effectively detect levels of amyloid aggregation in the brain by looking for two specific amyloid proteins in the cerebrospinal fluid.
A clinical trial testing Lumipulse on PET scans found it was 97 percent accurate in picking out patients with brain amyloid buildup.
William Hu, the researcher who worked on the development of the test, said: “If we are to make real progress against this terrible disease, the development of accurate AD (Alzheimer’s disease) using biomarkers found in cerebrospinal fluid or other body fluids ) testing is a requirement. The importance of early diagnosis for AD is widely recognized, but until now, there has not been an approved biomarker test available to clinicians and patients.”
The Lumipulse test is certainly not an easy test. The procedure for collecting a spinal fluid sample is not as simple as a blood test. The new test, however, will make amyloid measurements greatly accessible to more patients across the United States.
A statement from the FDA noted that the test is only available for adults over the age of 55 who are being evaluated by a doctor for Alzheimer’s disease.
The test is not intended to be used as a general screening or diagnostic tool, but to help doctors rule out early-onset Alzheimer’s disease in patients with neurological problems.
“The advent of an in vitro diagnostic test has the potential to eliminate the need for time-consuming and expensive PET scans for individuals and families concerned about the possibility of Alzheimer’s diagnosis,” said Jeff Shuren, FDA’s Director of Devices and Radiological Health. That’s good news. With the Lumipulse test, there is a new option, usually done the same day, that can give doctors the same information about the brain’s amyloid status — and without the risk of radiation — to help determine Whether the patient’s cognitive impairment is caused by Alzheimer’s disease.”
FDA approved new test for early detection of Alzheimer’s disease
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
